A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: A report from the Australia and New Zealand Children's Cancer Study Group

Cancer

Volumn 80, Issue 3, 1997, Pages 489-496

  Carpenter, Paul A ^a   White, Les ^a   McCowage, Geoffrey B ^c   Nayanar, Vimala ^a   Toogood, Ian ^b   Shaw, Peter J ^c   Lockwood, Lianne ^d   Tiedemann, Karen ^e  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Chemotherapy; Childhood; Cyclophosphamide; Dose escalation; Dose intensive; Recurrent; Tumor

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROBLASTOMA; PRIORITY JOURNAL; SOLID TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFANT; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0030861595     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970801)80:3<489::AID-CNCR17>3.0.CO;2-T     Document Type: Article

References (45)

1. White L, McCowage G, Kannourakis G, Nayanar V, Colnan L, Kellie S, et al. Dose intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors. A phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group. J Clin Oncol 1994;12:522-31.
2. Finkelstein JZ, Hittle RE, Hammond DG. Evaluation of a high dose cyclophosphamide regimen in childhood tumors. Cancer 1969;23:1239-42.
3. Schwann MR, Blattner SR, Lynch E, Weinstein HJ. HLC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukaemia. J Clin Oncol 1991;9:133-8.
4. Kushner BH, O'Reilly RJ, LaQuaglia M, Cheung NK. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma. Cancer 1990;66:1095-100.
5. White L. Chemotherapy in retinoblastoma current status and future directions. Am J Pediatr Hematol Oncol 1991; 13:189-201.
6. Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 1981;55:749-56.
7. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
8. Kushner B, Helson L. Co-ordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma. Experience with 100 patients. J Clin Oncol 1987;5:1746-51.
9. Griswold DP, Trader MW, Frei E, Peters WP, Wolpert MK, Laster WR. Response of drug-sensitive and resistant L1210 leukemias to high-dose chemotherapy. Cancer Res 1987; 47:2323-7.
10. Schuler U, Ehninger G, Wagnet T. Repeated high-dose cyclophosphamide administration in bone marrow transplant: exposure to activated metabolites. Cancer Chemother Pharmacol 1987;20:248-52.
11. Klein HO, Wickramanayake PD, Christian E, Coerper C. Therapeutic effects of single push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, asta Z 7557). Cancer 1984;54 (6 Suppl):1193-203.
12. Teicher BA, Holden SA, Eder IP, Brann TW, Jones SM, Frei E. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 1989;49:5994-8.
13. Smith IE, Evans BD, Harland SJ, Millar JL. Autologous bone marrow rescue is unnecessary after very high-dose cyclophosphamide. Lancet 1983;1:76-7.
14. Meissenberg B, Lassiter M, Hussein A, Ross M, Vredenburgh JJ, Peters WP. Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. Bone Marrow Transplant 1994;14:287-91.
15. Spector JI, Zimbler H, Ross JS. Early onset cyclophosphamide-induced interstitial pneumonitis. JAMA 1979;242: 2852-3.
16. Steinherz LI, Steinherz PG, Mangiacasale D, O'Reilly R, Allen I, Sorell M, et al. Cardiac changes with cyclophosphamide. Med Pediatr Oncol 1981;9:417-22.
17. Lilley ER, Rosenberg MC, Elion GB, Colvin OM, Bigenr DD, Friedman HS. Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. Cancer Res 1990;50:284-7.
18. Kalwinsky DK, Dahl GV, Mirro I, Look AT. Cyclophosphamide/etoposide: effective reinduction therapy for children with acute non-lymphocytic leukemia in relapse. Cancer Treat Rep 1985;69:887-9.
19. Saleh RA, Graham-Pole J, Cassano W, Abbot F, Vander Griend R, Dickson N, et al. Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy. Cancer 1990;65:861-5.
20. Spitzer TR, Cottler-Fox M, Torrisi J, Cahill R, Greenspan A, Lynch M, et al. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 1989;4:559-65.
21. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-81.
22. Ettinger LJ, Gaynon PS, Krailo MD, Ru N, Baum ES, Siegel SE, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. Cancer 1994;73:1297-301.
23. Pratt CB. Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia. Semin Oncol 1990;17:31-40.
24. Ettinger LJ, Ru N, Krailo MD, Ruccione KS, Krivit WA, Hammond GD. A phase II study of diaziquone in children with recurrent or progressive solid tumors. Report from the Children's Cancer Study Group. Am J Pediatr Hematol Oncol 1990;12:301-5.
25. Raney RB. Inefficacy of cisplatin and etoposide as salvage therapy for children with recurrent or unresponsive soft tissue sarcoma. Cancer Treat Rep 1987;71:407-8.
26. Cangir A, Starling KA, Hawkins EP, Ragab AH, Land VJ. Combination chemotherapy with vinblastine sulfate and bleomycin infusion in children with recurrent metastatic tumors. Proc Am Soc Clin Oncol 1982;1:172.
27. Castello MA, Clerico A, Jenkner A, Dominici C. A pilot study of high dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors. Pediatr Hematol Oncol 1990;7:129-35.
28. Pein F, Tournande MF, Zucker JM, Brutat-Mentigny M, Deville A, Boutard P, et al. Etoposide and carboplatin a highly effective combination in relapsed or refractory Wilms' Tumor - a phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994;12:931-6.
29. Hayes FA, Green AA, Casper J, Cornet J, Evans WE. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma response and toxicity. Cancer 1981;48:1715-8.
30. Oberlin O, Habrand J, Zucker JM, Brunat-Mentigny M, Terrier-Lacombe M, Dubousset J, et al. No benefit of ifosfamide in Ewing's sarcoma: a non-randomised study of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1407-12.
31. Shaw PJ, Eden T. Ifosfamide in paediatric oncology: tried but not tested? Lancet 1990;335:1022-3.
32. Kamen BA, Colvin OM. Ifosfamide: should the honeymoon be over? J Clin Oncol 1995;13:307-9.
33. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumours of children and young adults. J Clin Oncol 1987;5:1191-8.
34. Kung FH, Pratt CB, Vega RA, Jaffe N, Strther D, Schwenn M, et al. Ifosfamide/Etoposide combination in the treatment of recurrent malignant solid tumours of childhood. Cancer 1993;71:1898-903.
35. Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, et al. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphoma and solid tumors. J Clin Oncol 1992; 10:1712-22.
36. Marina N, Murry J, Rodman S, Shema S, Bowman L, Furman W, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide (ICE) in children with untreated malignancies [abstract]. Proc Am Soc Clin Oncol 1993;12:416.
37. Campbell LA, Seeger RC, Harris RE, Villablanca JG, Matthay K. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol 1993;11:623-9.
38. Méresse V, Vassal G, Michon J, De Cervens C, Courbon B, Ruble H, et al. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma a phase II study from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1993;11:630-7.
39. Bruggers CS, Friedman HS, Tien R, Delong R. Cerebral atrophy in an infant following treatment with ifosfamide. Med Pediatr Oncol 1994;23:380-3.
40. Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH. High-dose ifosfamide with uroprotection: a phase I study. J Clin Oncol 1990;8:170-8.
41. Ashraf MS, Brady J, Breatnach F, Deasy PF, O'Meara A. Ifosfamide nephrotoxicity in paediatric cancer patients. Eur J Pediatr 1994;153:90-4.
42. Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigioni P, et al. Allogeneic bone marrow transplant for children with acute myeloid leukemia: impact of conditioning regimen without total-body irradiation - a report from the Société Francaise de Greffe de Moelle. J Clin Oncol 1994;12:1217-22.
43. Quinones RR. Hematopoietic engraftment and graft failure after bone marrow transplantation. Am J Pediatr Hematol Oncol 1993;15:3-17.
44. White L. P-glycoprotein expression and prognosis of neuroblastoma. N Engl J Med 1992;326:1162.
45. Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W. Plasma half life and urinary excretion of cyclophosphamide in children. Cancer Treat Rep 1980;64:1061-6.